Sopharma

“Sopharma Trading” AD acquires sole control over the companies “SCS Franchise” AD and “Sanita Franchising AD, which strengthens its position on the pharmacy market.” "Sopharma" AD sold the shares owned by it from the capital of "Aromania" AD, after having mastered all significant brands and activities. Аs a result of lengthy negotiations and an agreement reached with the other shareholders, a change in the shareholder structure of the subsidiary SIA "BRIZ" was entered in the Commercial Register of the Republic of Latvia as a result of which "Sopharma" AD remains the sole owner of the capital of the company. Marketing Authorization was obtained for 5 new medicinal products - Solifenax 5 mg film-coated tablet (Bulgaria), Ambrolitin 30 mg/5 ml syrop (Bulgaria, Latvia, Estonia), Ketoprofen 100 mg/ 2 ml solution for injection (Bulgaria), Sofazolon 40mg powder and solvent for solution for injection (Bulgaria), Dexketoprofen 50mg/2ml solution for injection (Latvia, Lithuania, Estonia).

"Sopharma" AD registered the first generic - "Urimax duo" in the field of urology.

"Unipharm" AD is merged into "Sopharma" AD. The company celebrates its 85th anniversary.

"Sopharma" AD acquires 51% of the capital of the Moldovan distributor of medicinal products RAP Pharma International. "Sopharma" AD acquires 75% of the successful start-up for the development and marketing of Aromania food supplements. "Medica" AD is merged into "Sopharma" AD.

Sopharma AD acquires 68% of the capital of Veta Pharma AD.

Bulgarian Rose - Sevtopolis AD is finally merged into Sopharma. Sopharma Trading AD entered the Serbian Market.

After concluding the largest projects for modernization of the production facilities we can now put strong focus on R&D.

The new state-of-the-art solid-forms factory of Sopharma is operational and won three awards in the construction sector. The company takes several steps towards the consolidation of the Group.

For the first time in the modern history of the company we open a new administrative office, more accessible to our guests and partners. For a third consecutive year Sopharma is given the “Best public company” award from the Capital Top 100 ranking.

Listing on Warsaw Stock Exchange

Start of construction of two new production plants in Serbia and Bulgaria and establishing of a subsidiary in Poland.

Being the only producer of ampoules in Bulgaria in 2007 Sopharma undertook a reconstruction of its ampoule facility in order to increase its production capacity.

In 2007 Sopharma made the next step in modernization and increased production capacity in the tablet production of Bulgarian Rose - Sevtopolis AD, Kazanlak.

Sopharma initiated the planning and construction process of a new highly technological tablet factory for the production of solid forms with doubled capacity and investment potential of over 40 million EUR. All activities related to planning, construction and validation fully comply with the European standards for pharmaceutical production and are approved by the Bulgarian Health Agency. For this project Sopharma received the First Class Investor Award.

In 2005 Sopharma opened the most modern logistics center in Bulgaria (logistics terminal) for distribution of pharmaceutical products. The logistics center fully complies with the European Good Distribution Practice (GDP).

In 2004 Sopharma licensed its production facilities according to the European GMP which secured its strategic position after the EU accession in 2007. In the same year Sopharma increased its production capacity by adding another member to its group of companies - Bulgarian Rose - Sevtopolis AD.

The President of the Republic of Bulgaria George Parvanov officially opened the new pharmaceutical plant “Sopharma – Vrabevo”. In this modern plant for production of medicinal products Sopharma invested 20 million BGN. Each step of the construction of the plant followed internationally accepted GMP (Good Manufacturing Practices) standards.

After a successful privatization Sopharma becomes a private pharmaceutical company. The first years after privatization are a period of constant modernization and improvement. For the two years after the privatization period Sopharma unites six enterprises in a modern and dynamic corporate structure including: Sopharma AD, Unipharm ASD, Vramed AD, Pharmachim Holding AD, NIFHI AD and Rostbalkanpharm.

All machines for the production of solid forms are moved into the “Galenus” plant. The average production capacity of one machine reaches 5,576 tablets per hour. The main products are Aspirin, Chinin and Doverin produced with imported and high quality raw materials. In the same year, after the nationalization, the “Galenus” plant is renamed into Chemical-pharmaceutical plant – the ancestor of Sopharma.

The production laboratory of the Bulgarian Pharmacy Cooperative Company moves in a building especially constructed for its needs on “Iliensko shousee” and grows into “Galenus” – a pharmaceutical plant in which better conditions are a prerequisite for faster development. This leads to increase of production capacity and widening of the product portfolio. “Galenus” is the first modern industrial plant for production of medicinal products on the Balkan Peninsula, competing with popular German and Swiss companies.

The pharmaceutical community united in its economic organization “Bulgarian Pharmacy Cooperative Company” starts the construction of the first production laboratory for production of medicinal products in the country.